For more than four decades, pathologists have glimpsed something unsettling under the microscope in the earliest stages of certain cancers: cells with nuclei far larger than they should be, swollen and distorted, lurking in tissue that otherwise appears on the verge of catastrophe. These so-called giant-nucleus cells, or karyomegalic cells, were first spotted in the 1980s in animal experiments involving iron-induced oxidative stress, yet their biological identity and their role in the genesis of cancer remained stubbornly obscure. Now, a team of researchers in Japan has provided the most detailed portrait of these cells to date, and their findings suggest that the enormous nuclei may be far more than a curiosity—they could be the founding population of early cancer, visible before any tumor exists, and potentially useful as a predictor of patient outcomes.

The study, led by Shinya Toyokuni, professor emeritus at Nagoya University Graduate School of Medicine, together with assistant professor Yingyi Kong and colleagues, was published in Redox Biology. The work addresses a deceptively simple question: when iron overload kills most cells in a tissue through oxidative damage, who survives, and what do the survivors become? Iron is an essential micronutrient, but in excess it is a potent carcinogen. Its chemistry is both the reason we need it and the reason it can harm us. Iron catalyzes the formation of hydroxyl radicals from hydrogen peroxide through the Fenton reaction, and these radicals shred DNA, oxidize lipids, and damage proteins. When the damage is severe enough, a form of programmed cell death called ferroptosis is triggered—an iron-dependent demise characterized by lipid peroxidation cascades that rupture the cell membrane. Ferroptosis has become one of the hottest topics in cancer biology precisely because it links iron metabolism, oxidative stress, and cell fate in a single mechanism.

Toyokuni’s team reasoned that if ferroptosis sweeps through iron-damaged tissue, the cells that escape it must be exceptional in some way, and those exceptions might be the seed of malignancy. To find out, they turned to a well-established animal model in which ferric nitrilotriacetate, a carcinogenic iron compound, is injected into rats, delivering a bolus of iron to the kidneys. The compound accumulates in the proximal tubules, where it catalyzes oxidative damage and, over months, produces renal cell carcinoma. In the experiments, the researchers collected kidney tissue before the injection and again one and three weeks afterward. Crucially, they also included a second experimental group: rats carrying a single mutated copy of the BRCA1 gene, the same gene that, when mutated in humans, dramatically raises the risk of breast and ovarian cancers and is associated with renal carcinoma in certain contexts.

The methodological heart of the study lies in its marriage of two technologies. The first is spatial transcriptomics, a technique that maps gene activity across individual cells within a tissue section while preserving the tissue’s original architecture—so researchers can see not only which genes are active but where in the tissue those transcriptional programs are operating. The second is computational nuclear morphometry, which quantifies the size, shape, and density of cell nuclei in the same samples. By overlaying the two datasets, the team could link the physical appearance of each cell—above all, the size of its nucleus—to its underlying transcriptional state. This integration is important because morphological atypia has long been the currency of diagnostic pathology, but connecting that atypia to molecular signatures at single-cell resolution is a recent capability.

What emerged within a week of iron administration was striking. Giant-nucleus cells appeared in the damaged kidneys, and these cells were not simply wounded cells awaiting death. They showed elevated expression of potent oncogenes, including Myc and Met, and they had acquired resistance to ferroptosis—the very cell death pathway that was eliminating their neighbors. In other words, the extreme oxidative environment had functioned as a brutal selective pressure, and the cells best adapted to survive it had activated a program that resembles, in miniature, the hallmark machinery of cancer. The enrichment of Myc, a transcription factor that drives cell growth and proliferation, and Met, a receptor tyrosine kinase involved in invasive growth, paints a picture of cells that are not merely enduring damage but reorganizing themselves around it.

The BRCA1 connection proved equally consequential. BRCA1 is best known as a guardian of the genome, a scaffold for the homologous recombination machinery that repairs double-strand DNA breaks. In the BRCA1-mutant rats, giant-nucleus cells emerged with distinctly different biological profiles from those in wild-type animals. The interpretation the researchers offer is that BRCA1 deficiency cripples DNA repair, so more of the damaged cells that would otherwise die or be repaired instead survive in their injured, genome-compromised state—becoming precancerous giant-nucleus cells. Electron microscopy and cellular respiration measurements reinforced this idea at the subcellular level: cells from BRCA1-mutant rats showed mitochondrial remodeling, with impaired iron handling and compromised respiratory function. Mitochondria, long appreciated as power plants, are also central regulators of ferroptosis and iron metabolism, and their disarray in the mutant animals may be both a consequence of BRCA1 loss and a driver of the abnormal iron biology that feeds karyomegaly.

Using their combined gene-expression and nuclear-shape data, the researchers went further and classified the giant-nucleus cells into six distinct types. One type possessed extremely large nuclei and gene signatures of stress-induced growth arrest—cells that appear to have locked themselves into a senescent-like state, consistent with profiles reported in earlier studies. Another type, found more frequently in BRCA1-mutant kidneys, showed heightened activity of cancer-related genes alongside elongated nuclei, a combination the authors interpret as a potential precancerous state. The taxonomy matters because it reframes giant-nucleus cells from a single enigmatic category into a spectrum, some members of which may be harmless or even protective while others carry genuine malignant potential.

One of the most provocative findings concerns the cells surrounding the giants. Even morphologically normal cells near giant-nucleus cells exhibited gene expression changes that appear to promote survival, suggesting that the karyomegalic cells remodel their local microenvironment in ways that extend beyond their own borders. In BRCA1-mutant kidneys, the team also documented a substantial increase in stromal cells—non-cancerous supportive cells including immune and connective tissue elements—around the damaged regions. The local tissue environment, the tumor niche in the language of modern oncology, was being reshaped long before any tumor could be called a tumor. This raises the possibility that a single conspicuous cell, easily identified by its nucleus under a conventional microscope, could serve as a sentinel for a whole neighborhood of incipient malignancy.

The leap from rat kidneys to human medicine came through two complementary analyses. First, the researchers mined TCGA-KIRC, a large public database of kidney cancer patients, asking whether tumors carrying gene-expression patterns resembling the cancer-prone giant-nucleus cells were associated with different clinical trajectories. They were: patients whose tumors shared the gene patterns of the cancer-prone giant-nucleus cells had shorter survival times, while those with patterns resembling the healthier giant-nucleus cell types had better outcomes. Not all giant-nucleus cells, in other words, are created equal, and the transcriptional fingerprints defined in the rat model appear to carry prognostic weight in human disease. Second, in a small pilot study, the team examined breast tissue from seven individuals with inherited BRCA1 mutations and fifteen without, observing abnormal nuclear features similar to those in the animal model in the mutation carriers. While the sample size is modest, the parallel hints that karyomegaly may be a cross-tissue marker of BRCA1-linked precancerous change.

The broader implications run in two directions. Clinically, the promise is that giant-nucleus cells, being easy to spot under the microscope, could function as early indicators of cancer—visible warnings in tissue that would otherwise be classified as merely damaged or inflamed. The TCGA survival data suggest that their gene-expression signatures might even stratify patients by risk once a tumor has formed. Scientifically, the study offers a concrete mechanism connecting an environmental exposome factor—iron-catalyzed oxidative stress—to a defined, transcriptionally characterized precancerous population, with ferroptosis resistance as the pivot. It also implies testable therapeutic hypotheses: if blocking mitochondrial remodeling or reversing ferroptosis resistance could prevent the persistence of the precancerous cells, early intervention might stop cancer before it starts. Toyokuni and his colleagues are careful to note that long-term studies will be needed to determine how giant-nucleus cells actually progress into tumor cells, whether such interventions can work, and whether nuclear shape combined with gene patterns can be validated as a diagnostic in larger patient cohorts. But the central message is already legible: some of the earliest chapters of cancer may be written in cells that have grown too large to be ignored.

Researchers at the Helmholtz-Zentrum Berlin (HZB) in Germany have overcome a long-standing barrier in next-generation photovoltaics by developing a new type of all-perovskite triple-junction solar cell. Perovskites are a class of synthetic materials with a unique crystal structure that excel at absorbing light, while a triple-junction design stacks three distinct perovskite sub-cells together, each tuned to capture a different part of the solar spectrum to maximize energy harvesting. With this combination, the device achieved a power conversion efficiency of 27.3%.

Stacking three such individual sub-cells allows multi-junction devices to bypass the theoretical efficiency ceiling of traditional single-junction solar cells. However, their real-world implementation has been severely constrained by optical and electrical losses at the buried interfaces of their narrow-band-gap sub-cells. By introducing a novel graphene oxide and self-assembled monolayer (SAM) bilayer strategy, the HZB team has effectively suppressed these losses, unlocking both high efficiency and unprecedented operational stability.

The challenge of buried interfaces

The main bottleneck in multi-junction all-perovskite architectures centres on the narrow-band-gap tin-lead bottom sub-cell, which captures near-infrared light. For years, the field has relied on an organic polymer called PEDOT:PSS as the hole-transport layer to extract positive charges from this sub-cell. However, PEDOT:PSS suffers from a high degree of parasitic light absorption, robbing the underlying bottom cell of valuable incoming photons. Furthermore, its highly acidic and hygroscopic nature chemically degrades the sensitive perovskite material, creating a critical compromise between efficiency and device lifespan.

This results in a severe material trade-off, whereby a layer intended to extract electric charge ends up blocking the very light needed to generate that charge, all while slowly destroying the underlying solar cell structure.

To move away from PEDOT:PSS, researchers have frequently looked to SAMs, molecularly engineered alternatives that perform exceptionally well in pure lead-based perovskites. Yet, when deposited directly onto tin-lead perovskite layers, SAMs present an unexpected physical anomaly, triggering severe internal electrical field screening and inducing uneven grain growth at the buried interface. Using fast-hysteresis measurements and bias-assisted charge extraction measurements, the HZB team discovered that standard carbazole-based SAMs lead to massive ion accumulation, which severely hinders the cell’s ability to separate and extract photogenerated charge carriers.

Unlocking charge flow with a molecular bilayer

Led by Steve Albrecht, the HZB team designed a synergistic bilayer to circumvent this destructive ion accumulation and field-screening mechanism. They deposited an ultrathin, uniform layer of hydrophilic graphene oxide directly onto the transparent indium tin oxide conductive base, before introducing a specialized SAM molecule, MeO-2PACz. The phosphonic acid head groups of the SAM anchor strongly onto the oxygen-containing functional groups of the graphene oxide via hydrogen and covalent bonding.

This chemical arrangement prompts a favourable molecular reorientation that deepens the layer’s electronic work function, markedly enhancing its electrical conductivity. Additionally, the graphene oxide provides a smooth, hydrophilic foundation that accelerates crystal nucleation, generating a uniform, high-quality perovskite film completely free of the microscopic empty spaces (nanovoids) that plague SAM-only devices in this study.

When integrated into single-junction tin-lead solar cells, the new bilayer achieved a standalone power conversion efficiency of 22.1%, heavily outpacing the 12.0% efficiency of SAM-only equivalents. Using optoelectronic characterization, the team confirmed that this massive improvement was driven almost entirely by the mitigation of internal electronic and ionic extraction losses.

Record stability and the path to 30%

The researchers demonstrated the true potential of this technique when they integrated the bilayer into a monolithic triple-junction stack featuring sub-cells with band gaps of 2.00, 1.60 and 1.25 eV. By replacing the conventional gold and PEDOT:PSS interconnecting layers with an optimized indium tin oxide and graphene oxide/SAM bilayer configuration, they minimized parasitic light absorption in the near-infrared spectrum. This structural optimization raised the short-circuit current density of the narrow-band-gap bottom cell to 10.3 mA/cm², driving the overall triple-junction efficiency to 27.3%.

Beyond the efficiency milestone, the chemically benign and robust nature of the graphene oxide/SAM interface yielded exceptional longevity. While traditional PEDOT:PSS-based cells degrade rapidly due to chemical interactions, the encapsulated bilayer devices successfully retained 90% of their initial performance after 770 h of continuous operational tracking under 1-sun illumination at room temperature. This sets a new stability record for triple-junction all-perovskite configurations.

The team notes that the current triple-junction performance is still bound by slight current mismatches and series-resistance transport losses across the interconnecting sub-cell junctions. By further optimizing the quality of the wider-band-gap perovskite layers and fine-tuning the band alignments of the intermediate contacts, the researchers project that the efficiency of this multi-junction solar architecture can comfortably clear the 30% barrier in the near future.

The solar cell design is detailed in Joule.

The post Bilayer approach ramps performance of all-perovskite triple-junction solar cells appeared first on Physics World.

A compound produced in the body after eating pomegranates improved heart function by up to 80% in experimental models of a type of heart failure with limited treatment options. For people with heart failure with preserved ejection fraction, the heart can still pump blood but struggles to relax and refill properly between beats. In experimental [...]

That’s now just 1 billion years for all the apparatus to hit on the lucky combination randomly, unless we start with design principles.

Source

How immune cells develop and retain memory may work differently than medical scientists previously believed, according to an international team of researchers.

The new work shows that T cells—white blood cells essential to immune function—can respond to the physical properties of their surroundings through a kind of cellular sense of touch.

The researchers published the work in Nature Immunology, altering our understanding of how immune cells develop, and potentially improving scientists’ understanding of how the immune system adapts to the varied physical environments found throughout the human body.

T Cells Explained

The various specialized types of T cells serve crucial roles in the immune system. Some directly fight infections, while others help coordinate the immune response. Scientists have long believed that biochemical signals help shape the memory T cells that persist in tissues following an infection, preserving the body’s ability to respond to previously encountered threats. How these cells migrate and eventually settle into strategic positions throughout the body is a key part of the immune response.

As T cells travel through the body, they continually monitor for signs of pathogens. When a threat is detected, T cells can enter affected tissues and help clear the infection. Once the invaders have been repelled, some T cells remain in the tissue to guard against reinfection. These tissue-resident memory T cells help defend against previously encountered threats but can also play roles in autoimmune disorders and the rejection of transplanted tissue.

Over their lifetimes, T cells can develop into increasingly specialized forms. Naive T cells have not yet encountered the specific antigen they are capable of recognizing. Following activation, they can differentiate into effector T cells that help target a particular threat, with some eventually developing into long-lived memory cells.

Tissues in the Body

Tissues in our bodies vary widely in stiffness, ranging from the very soft adipose tissue that makes up our body fat to the much stiffer skeletal muscle tissue. These differences raise an interesting question: how do T cells remain strong enough to survive the pressures of stiffer tissues while staying soft enough to change shape as they slide through obstacles in our bodies?

For their laboratory experiments, the researchers reproduced typical tissue stiffnesses using specially engineered collagen gels. They then placed human and mouse immune cells into the gels and discovered that T cells were more likely to develop characteristics associated with tissue-resident memory cells in stiffer environments.

Previously, scientists believed biochemical signals were the primary driver of tissue-resident memory T cell development. In their new research, the team found that these cells use touch to sense the mechanical pressure of their surroundings, dictated by tissue stiffness, and adjust their morphology to compensate.

“This is an exciting fundamental finding that challenges the way we think about immune cells,” said lead author Judith Mandl, a professor in McGill University’s Department of Physiology. “It suggests T cells can ‘feel’ their surroundings and adapt to them, making the physical environment an active force in shaping their behaviour.”

Correcting T Cells

While T cells normally function to protect us from illness, they can occasionally create problems of their own. Patients with autoimmune diseases and allergies may see these immune cells begin attacking healthy tissue. Additionally, organ transplant patients typically require immunosuppressant drugs to stop their T cells from rejecting the new organ.

“Tumours are often dense and physically difficult for immune cells to penetrate. Understanding how T cells adapt to these environments could help researchers design cancer immunotherapies that are better able to reach and attack tumours,” said Mandl.

This new research is an important first step in a new understanding of how immune cells differentiate, which could lead to a new foundational understanding of how to correct undesired immune responses.

The paper, “Mechanosensing by T Cells Promotes a Tissue-Resident Memory Transcriptional Program,” appeared in Nature Immunology on July 3, 2026.

Ryan Whalen covers science and technology for The Debrief. He holds an MA in History and a Master of Library and Information Science with a certificate in Data Science. He can be contacted at ryan@thedebrief.org.

A protein called TRAILshort may act as a central immune brake that limits T-cell responses and CAR-T therapy. Cancer cells can weaken the immune system by producing a protein that prevents its most important defenders from attacking. Mayo Clinic researchers have identified how this protein works, revealing a possible target for treatments designed to improve [...]

Fuchs endothelial corneal dystrophy, a progressive disorder that can gradually cloud the cornea and impair vision, may be driven by a cellular process more complex than simple cell loss. A new study published in Cell Death Discovery reports that ultraviolet-A light can induce chronic hyperploidization in corneal endothelial cells, triggering changes associated with fibrosis. The findings connect long-term genome abnormalities in post-mitotic cells to the structural deterioration observed in this increasingly recognized eye disease.

The cornea depends on a thin inner layer of endothelial cells to maintain its transparency. These cells regulate the movement of fluid between the cornea and the anterior chamber of the eye, preventing the tissue from becoming waterlogged. Unlike many cell types, human corneal endothelial cells have limited ability to divide and replenish themselves. When they are damaged or lost, neighboring cells may enlarge and stretch to cover the affected area, but this compensation has limits. In Fuchs endothelial corneal dystrophy, the endothelial layer progressively becomes dysfunctional, allowing fluid accumulation and producing corneal swelling, haze and visual distortion.

The study focuses on hyperploidization, a condition in which cells acquire extra sets or copies of chromosomes. In a healthy cell cycle, DNA is replicated and then evenly distributed when a cell divides. Post-mitotic cells, however, are not expected to continue cycling through repeated rounds of DNA replication. If DNA replication occurs without successful cell division, the result can be a cell with an enlarged genome and multiple chromosome sets. This state, known as polyploidy or hyperploidization depending on its extent and context, can alter cell size, metabolism, gene activity and responses to stress.

The researchers investigated how ultraviolet-A, or UVA, light affects cells associated with Fuchs endothelial corneal dystrophy. UVA has a longer wavelength than ultraviolet-B and can penetrate biological tissues more deeply. Although the eye possesses protective mechanisms, persistent or excessive exposure to light-generated stress can damage cellular components, including DNA, proteins and mitochondria. The study indicates that UVA exposure does not merely cause an acute injury that cells either repair or fail to survive. Instead, it can establish a chronic hyperploid state in cells that no longer divide normally.

That distinction is important because a cell can remain alive while becoming increasingly dysfunctional. Hyperploid cells may continue to produce proteins, communicate with neighboring cells and modify their surrounding environment, even as their enlarged genomes disrupt normal regulation. In the corneal endothelium, such persistent abnormalities could interfere with the machinery responsible for maintaining fluid balance and tissue transparency. The research links this long-lasting cellular state to the activation of fibrotic processes, suggesting that damaged endothelial cells may help remodel the cornea rather than simply disappearing.

Fibrosis is the formation or accumulation of excessive connective-tissue components, particularly extracellular matrix proteins such as collagens. During wound healing, matrix production can provide temporary structural support. When the response persists, however, the tissue can stiffen, become disorganized and lose its normal optical properties. In the context of Fuchs endothelial corneal dystrophy, fibrosis may contribute to the loss of corneal clarity and the progression of visual impairment. The study’s central message is that chronic hyperploidization may act as an upstream signal that pushes post-mitotic cells toward this pathological remodeling.

The findings also help explain why a disease affecting a specialized, non-dividing cell population can progress over time. A conventional view of cellular damage often emphasizes apoptosis, necrosis or the gradual depletion of functional cells. The new work highlights another possibility: injured cells may survive in a permanently altered condition and actively influence disease progression. By retaining metabolic activity while carrying abnormal quantities of DNA, these cells could produce signals that encourage inflammation, matrix deposition or changes in the behavior of nearby cells.

The UVA connection raises questions about how environmental stress interacts with inherited susceptibility. Fuchs endothelial corneal dystrophy has genetic and age-related components, and the disease does not arise from a single universal cause. The study does not establish that UVA exposure alone causes the disorder, but it provides a mechanism through which light-associated stress could worsen cellular instability in vulnerable corneal tissue. This may help researchers examine whether cumulative exposure, cellular antioxidant capacity and pre-existing genetic changes combine to determine how rapidly the disease advances.

From a treatment perspective, the work points toward targets beyond replacing lost endothelial cells. Future strategies might seek to prevent abnormal DNA replication, stabilize genome integrity, suppress the fibrotic signals released by hyperploid cells or protect the corneal endothelium from chronic light-induced stress. Such approaches would require careful testing, because polyploidy can serve useful roles in some normal tissues, and broadly blocking cell-cycle or repair pathways could produce harmful effects. The challenge will be to distinguish pathological hyperploidization from adaptive genome changes that help cells survive.

The study ultimately presents Fuchs endothelial corneal dystrophy as a disease of cellular identity as well as cellular survival. UVA-induced chronic hyperploidization appears to place post-mitotic corneal endothelial cells in a persistent state of genomic imbalance, where they can contribute to fibrosis and tissue failure. By connecting light stress, abnormal DNA content and corneal scarring, the research offers a new framework for understanding why the disease can continue even after the initial injury has passed—and provides a potential roadmap for therapies designed to interrupt the process before vision is permanently compromised.

Subject of Research: Ultraviolet-A light-induced chronic hyperploidization and fibrosis in post-mitotic corneal endothelial cells affected by Fuchs endothelial corneal dystrophy

Article Title: Ultraviolet-A light-induced chronic hyperploidization causes fibrosis in post-mitotic cells affected by Fuchs endothelial corneal dystrophy

Article References: Adhikari, Y., Parekh, M., Deshpande, N. et al. Ultraviolet-A light-induced chronic hyperploidization causes fibrosis in post-mitotic cells affected by Fuchs endothelial corneal dystrophy. Cell Death Discov. (2026). https://doi.org/10.1038/s41420-026-03292-8

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41420-026-03292-8

Keywords: Fuchs endothelial corneal dystrophy, ultraviolet-A, UVA, hyperploidization, polyploidy, corneal endothelial cells, fibrosis, post-mitotic cells, genome instability, corneal disease

T cells may use a previously unknown CD64-dependent pathway to attack acute myeloid leukemia. T cells are generally thought to identify cancer through a well-established molecular recognition system. Yet when researchers removed a key part of that system from acute myeloid leukemia (AML) cells, the immune cells continued killing them. The unexpected result led scientists [...]

Macrobiological features have been cited as irreducibly complex, including animal joints and the trap mechanisms of carnivorous plants, even the cell itself.

Source

A protein and signaling pathway may help overcome the developmental block that keeps some leukemia cells immature. Inside the bone marrow, immature blood cells normally pass through a tightly controlled sequence of development before taking on specialized roles. In aggressive forms of leukemia, some of these precursor cells become trapped partway through that process. Instead [...]

The Varta crisis has entered another severe phase after the German battery manufacturer lost the customer responsible for nearly all production at its specialized factory in Nördlingen.

Varta has not publicly identified that customer, but reports from German media and industry sources point to Apple. The iPhone maker is reportedly moving battery orders for a future AirPods generation to a lower-cost supplier in China.

The decision will lead Varta to stop producing rechargeable button cells in Nördlingen during fall 2026. Approximately 350 jobs will be eliminated across the factory and the company headquarters in nearby Ellwangen.

Describing the development as a complete corporate collapse would go too far. Varta continues operating other battery businesses and recently completed an extensive financial restructuring backed by Porsche. The loss of Apple, however, has destroyed the economic foundation of a production site created around one highly influential customer.

Varta Crisis Exposes Dependence on Apple

The Varta crisis illustrates how a large technology customer can transform a supplier and then leave it with capacity that cannot easily be reassigned.

Varta became an important producer of CoinPower lithium-ion cells, small rechargeable batteries designed for wireless earbuds and other compact devices. Teardowns of AirPods Pro models identified Varta cells inside the earbuds, although Apple does not publicly discuss most component suppliers by product.

Demand from premium wireless headphones helped Varta expand rapidly. In 2020, its Microbatteries and Solutions division generated approximately €508 million in revenue, representing growth of 49% from the previous year.

The company invested heavily in production as wireless earbuds became a mass-market category. Apple demand provided the volume needed to justify specialized lines, equipment and hiring in Germany.

That dependence became dangerous when AirPods production weakened and Apple began adding other battery suppliers. A factory developed for unusually large orders could not operate efficiently once those orders declined.

The customer now leaving Nördlingen had previously accounted for nearly the entire capacity of the site. Varta says it has gained other customers, but their combined demand is not sufficient to keep the specialized factory running.

The plant is therefore closing not because rechargeable button cells have disappeared, but because replacing one customer of Apple scale requires far more than several smaller contracts.

Price Reportedly Decided the AirPods Order

German reports indicate that price was the decisive factor behind the supplier change.

Varta battery quality was reportedly equal to or better than the competing product. The German manufacturer could not, however, match the cost offered for the next generation of cells from China.

Battery production in Germany faces higher labor, energy and operating expenses than many Asian manufacturing centers. Chinese suppliers also benefit from extensive domestic electronics supply chains, access to materials and production volumes spread across numerous customers.

Apple has enormous leverage when negotiating component contracts. AirPods ship in sufficient quantities for a small difference in the cost of each battery to produce substantial savings across an entire product cycle.

The company regularly qualifies multiple suppliers for components when technical requirements and available capacity permit. Competition can reduce prices, protect production against interruptions and prevent one manufacturer from gaining excessive influence over the supply chain.

For Varta, that process brought the opposite effect. The supplier expanded to serve Apple and then faced declining utilization as the customer divided orders among additional manufacturers.

The latest move appears more final. Varta expects the contract to expire at the end of October, removing the volume that kept Nördlingen economically viable.

Apple Supplier Strategy Is Not Simply About China

The reported decision does not mean Apple is moving its complete production network toward China.

Apple has spent several years expanding device assembly and component production in India, Vietnam and other countries. AirPods manufacturing has grown in India, while Macs, iPads and wearables are assembled across a wider group of Asian locations.

The Varta case concerns a particular component for which a Chinese supplier reportedly offered a more competitive price. It shows that diversification away from one country can coexist with cost-driven sourcing from that same country.

Apple may reduce its dependence on Chinese final assembly while continuing to purchase Chinese batteries, displays, enclosures or electronic components when suppliers provide the required scale and pricing.

That balance creates a difficult environment for European manufacturers. Political interest in domestic technology production does not guarantee that major customers will accept higher component prices.

Premium engineering can protect a contract when it produces a measurable advantage in battery capacity, safety, dimensions or lifespan. Once competing suppliers reach comparable performance, procurement decisions become increasingly sensitive to cost.

The Varta crisis suggests that manufacturing location and supplier history carried less weight than the economics of the next AirPods battery.

Varta Was Already Fighting Financial Failure

Apple did not create every problem affecting Varta.

The company entered the current dispute after years of debt, costly investments, volatile customer orders, supply-chain problems and weaker demand in parts of its energy-storage business. A cyberattack in early 2024 also disrupted production and delayed financial reporting.

Varta warned that its earlier restructuring plan might fail after Apple reduced AirPods production. By mid-2024, the company had reached a point where it could no longer service its debt without another intervention.

A pre-insolvency restructuring reduced financial liabilities from approximately €485 million to €200 million. Porsche and majority shareholder Michael Tojner agreed to provide new capital, while creditors supplied additional financing.

Existing shareholders lost their investment as Varta was removed from the stock market. The process preserved the operating company but demonstrated how little financial room remained for another major disruption.

Varta reported a loss of €64.5 million for 2024. Although that was an improvement from the previous year, the business remained dependent on successful restructuring and stronger performance from its surviving divisions.

The Apple contract loss therefore did not independently bring down a healthy battery group. It struck a manufacturer that had already narrowly avoided insolvency.

Porsche Cannot Protect Every Varta Business

Porsche participation gives Varta a future in automotive batteries, but it does not rescue the Nördlingen button-cell operation.

The automaker invested in the restructuring and took control of the V4Drive business, which develops high-performance cylindrical lithium-ion cells for hybrid and performance vehicles. Porsche gains greater access to battery technology while helping retain part of that expertise in Germany.

Varta also continues producing household batteries and energy-storage systems. Those businesses serve different customers and do not depend on the machinery used for tiny CoinPower cells.

Employees affected by the Nördlingen closure may be offered positions at other locations, although Varta has not indicated how many can realistically be transferred. The company and its works council are negotiating measures for the workers whose roles will disappear.

The shutdown leaves a modern production unit without enough demand only a few years after wireless earbuds were presented as one of Varta most promising growth markets.

Its remaining automotive operation now has the security of a strategic customer with a direct ownership interest. The microbattery division learned the cost of building a factory around a customer that never made the same commitment.

The post Varta Crisis Deepens After Apple Battery Defection appeared first on AppleMagazine.

Cancer, arthritis, and diabetes can develop when cells activate the wrong genes. Yet, those failures are remarkably rare.

Researchers are turning toxic, centuries-old ammunition into highly efficient and cheap solar panels.

Aging appears to alter how key cerebellar neurons fire, with measurable effects on movement and coordination. Aging often brings slower movement, weaker balance, and reduced agility, but the brain changes behind these losses have been difficult to identify. McGill University researchers have now directly linked declining activity in Purkinje cells, an important type of neuron [...]

Controlling ribosomal RNA could help researchers target diseases driven by too little or too much protein production. Cells do not simply make proteins at a fixed pace. They continually adjust production to match their needs, and those changes can help determine whether a cell keeps dividing, adopts a specialized identity, or retains the developmental flexibility [...]

Researchers have developed the first entirely artificial cell, made completely from non-living chemical components, which they say is even capable of replicating.

A team of researchers at the University of Minnesota, Twin Cities, College of Biological Sciences, has described their synthetic cell, which they call SpudCell, in a recent preprint. SpudCell marks the first time scientists have replicated elements of life, such as energy use, reproduction, growth, and development, in a synthetic biological organism.

The Secrets of Life

While many mysteries of life and death remain for science, the team’s achievement represents a significant breakthrough, moving a concept once relegated only to science fiction into science fact. The team is hopeful that new solutions to medical and engineering problems will also arise from their achievement.

“This is likely the most exciting project I’ve ever worked on,” said co-author Kate Adamala. “We’ve replicated in chemistry what only used to be possible in biology: the complete set of behaviors of a cell. It proves that the most fundamental functions of life, like growth and replication, do not need a mysterious magical spark.”

The artificial SpudCell performs some of the most complex activities of its biological counterparts, including selection, genome replication, genetically encoded division, resource acquisition via feeding, and growth. 

Like a Cell, Yet Different

Although the synthetic cell copies many biological functions, there are some differences. It lacks the internal scaffolding, called a cytoskeleton, which natural cells use to divide. Instead, SpudCell crowds proteins together on its membrane surface until enough mechanical stress builds up to cause the membrane to split. 

In addition to being slightly different from a biological cell, the team refined SpudCell throughout their research, at one point altering the cell’s genetics to increase fusion protein production. With this change, the cells grew faster and produced more offspring, outcompeting the original variant in five generations. In a demonstration of the system’s selection and competition, the genetically modified advantage further increased when the team changed conditions to make nutrients scarcer.

The cell’s genetic code is relatively simple. There are about three million kilobase pairs in the human genome, and likely around 113 pairs in a single cell. SpudCell contains a mere 90, encoded on seven DNA plasmids, instead of a single chromosome. This encoding solution offers benefits, allowing researchers to program cellular functions more easily by simply touching a single piece of the modular system. They say this will enable them to continue increasing SpudCell’s complexity.

Moving Forward on Synthetic Cells

“This work is just the beginning,” said Adamala, who, along with several partners, is founding a research and engineering institution called Biotic, which will focus on further advancements in synthetic cell research, keeping its findings open source.

“We are showing it’s possible to engineer the basic functions of the cell,” Adamala added. “To fully realize the promise of this technology – to make it robust and practical – we need combined international effort.”

“The role of Biotic is to focus engineering efforts and make them compatible with a shared chassis. SpudCell is that chassis, and with Biotic setting the protocols for collaboration, we are eager to start applying this technology to serious challenges.”

The next steps for Biotic will be to combine SpudCell’s seven DNA plasmids into a single genome and build more molecular machinery. One of the greatest challenges they are preparing to confront is standardization, as many labs use different standards. To achieve true growth in this sector, Biotic aims to develop modular standards that will apply across the entire field.

SpudCell could provide a revolutionary new basis for manufacturing, allowing cells to naturally develop properties that typically require difficult and expensive molecular transformations, and even open up possibilities beyond what those transformations can offer. This could enable major improvements in medicine by using amino acids that are never used in nature.

The paper, “A Chemically Defined Synthetic Cell Capable Of Growth And Replication,” is available in preprint form on bioRxiv.

Ryan Whalen covers science and technology for The Debrief. He holds an MA in History and a Master of Library and Information Science with a certificate in Data Science. He can be contacted at ryan@thedebrief.org, and follow him on Twitter @mdntwvlf.

In a groundbreaking fusion of cutting-edge technology and dermatological research, scientists at Biohub have unveiled novel therapeutic targets for psoriasis by conducting the first comprehensive genome-wide CRISPR screen in primary human adult skin cells. By overcoming the longstanding technical hurdle of delivering CRISPR components into notoriously resistant keratinocytes without toxicity, the team utilized centrifuge-based transfection to probe the genetic regulators involved in psoriasis, a chronic inflammatory skin disorder affecting millions globally.

This innovative approach involved knocking out approximately 19,000 genes in keratinocytes sourced from human donors using a vast CRISPR guide RNA library. The focus was on modulating IL17RA, a pivotal receptor that mediates skin inflammation, to chart a genome-wide landscape of genes influencing inflammatory pathways directly in the skin’s outermost layer. The resultant massive data set was then mined using an AI-driven model, VirtualCRISPR, which cross-referenced each gene’s significance against existing scientific literature to highlight previously unrecognized contributors to psoriasis pathology.

Strikingly, this AI-guided screen pinpointed two promising protein targets: ALOX5, an enzyme targeted by the asthma medication zileuton, and OXTR, the gene encoding for the oxytocin receptor, a surprising candidate unassociated before with skin inflammation. Validation experiments in 3D reconstructed human skin cultures demonstrated that zileuton modulates keratinocyte metabolism to suppress inflammation independently from immune cells, revealing a direct pharmacological avenue.

Importantly, topical formulations containing zileuton and cligosiban, an OXTR antagonist, were tested in a mouse model of psoriasis, achieving comparable efficacy to standard injected biologics that broadly suppress immune function. Beyond mitigating inflammation, OXTR inhibition appeared to restore skin barrier integrity—a crucial factor in chronic disease progression—spotlighting this receptor as a novel therapeutic axis.

Unlike current systemic therapies, which often carry risks of broad immunosuppression and high costs, these localized topical interventions promise targeted treatment with minimal systemic exposure. Moreover, the safety profiles of zileuton and OXTR antagonists are well-established in clinical settings, potentially accelerating their repurposing for dermatological applications.

This study exemplifies the transformative power of integrating AI with high-dimensional genetic screening to unravel complex disease mechanisms in cell types previously inaccessible to large-scale functional genomics. By enabling direct investigation into keratinocyte biology, the research not only charts a course for new psoriasis treatments but also sets a precedent for applying similar methodologies to other inflammatory conditions.

As psoriasis affects roughly 125 million people worldwide, innovations enabling precise, effective, and safer therapies could revolutionize patient care. Biohub’s approach heralds a new era where AI-guided CRISPR screens expedite the discovery of unexpected drug targets and foster the development of locally acting, biology-informed treatments.

---

Subject of Research: Psoriasis therapeutic targets via genome-wide CRISPR screening of human skin cells

Article Title: AI-guided CRISPR screening reveals therapeutic targets in psoriasis

News Publication Date: 8-Jul-2026

Web References:
https://www.nature.com/articles/s41467-026-75249-5

References:
DOI: 10.1038/s41467-026-75249-5

Image Credits: Biohub

Keywords

Psoriasis, CRISPR, Oxytocin receptor, ALOX5, Zileuton, Cligosiban, Keratinocytes, AI-guided screening, Inflammation, Topical therapeutics

Experiments exploring the effects of missing a night’s sleep on the human brain have found indications that a sleepless night actually increases connections between brain cells instead of impeding growth. However, the lack of sleep could also create brain “fatigue” and pressure, resulting in burnout.

The Forschungszentrum Jülich Institute of Neuroscience and Medicine team behind the discovery said that their findings might support the idea that sleep plays an important role in restoring the brain’s cellular balance.

Missing a Night’s Sleep Could Disrupt Cellular Balance

In a statement announcing the surprising discovery, study leader David Elmenhorst and colleagues note that scientists still are not in complete consensus about why humans and other animals need sleep. One proposal involves restoring synaptic connections between brain cells during certain stages of sleep, helping the brain maintain a form of cellular ‘homeostasis.’

For example, previous research has shown that synaptic connectivity increases during wakefulness. This increased activity also increases energy consumption, potentially resulting in problematic protein buildup. Conversely, scientists suspect that sleep helps restore baseline synaptic connections and protein levels, thereby maintaining a healthy cellular balance.

“Sleep is essential for synaptic homeostasis, a proposed mechanism whereby wake­fulness leads to synaptic potentiation, and sleep facilitates synaptic down-selection,” the research team explains in a recently published study.

Although previous studies suggest that missing a night’s sleep could disrupt this balance, the team notes that there is very little experimental data to support these conclusions.

Study Reveals Elevated Synaptic Activity After 28 Hours Awake

To explore the role of sleep in cellular homeostasis in the human brain, the researchers used an advanced brain-scanning technology called positron emission tomography (PET). According to the team’s statement, this tool can scan the human brain for signs of synaptic vesicle glycoprotein 2A (SV2A),  which they describe as a “marker” of brain synapses.

The team started by enlisting 40 study volunteers. Next, each volunteer was given a PET scan to establish baseline marker levels. After their first scan, 20 of the volunteers were told to get a normal night’s sleep. According to the study authors, the second half were assigned to “the sleep deprivation condition,” where they were told to miss a night’s sleep.

The next day, the team used the PET scan to search for telltale brain synapse markers. As hoped, the scans revealed a distinct difference between the two groups. Where the normal sleep group’s levels were within expected ranges, the synapse markers of the volunteers who had missed a night’s sleep were elevated.

A closer analysis found that once people passed 28 hours of continued wakefulness, their SV2A markers were higher “in several brain regions.” Notably, these increased markers were detected in the hippocampus, which plays an important role in memory, and in the thalamus, which is critical for information relay within the brain.

“Sleep deprivation led to significant increases in synaptic vesicle glycoprotein 2A binding in multiple brain regions, including the thalamus (+4.6%), hippocampus (+5.6%), and parietal cortex (+3.2%), whereas no changes were observed in controls,” the study authors write.

Sleep Deprivation Causes Fatigue and CHanges Neural COnnections

When discussing the study’s limitations, the authors note that the SV2A marker used is a “proxy” for connections between brain cells, not a direct measure. They also note that the observed changes after a missed night’s sleep “were relatively small.” Still, they add, the results in several regions across several study participants “suggest a biological connection between the need for sleep and the buildup of cell connections.”

“During sleep deprivation, the brain remains awake longer and continues to process stimuli and information,” they write. “Our study shows that after approximately 28.5 hours of wakefulness, a marker for synaptic density increases in several brain regions. This suggests that sleep deprivation not only causes fatigue but is also accompanied by measurable changes in neural connections.”

The study “Sleep deprivation increases levels of the synaptic density marker SV2A in the human brain” was published in PLOS Biology.

Christopher Plain is a Science Fiction and Fantasy novelist and Head Science Writer at The Debrief. Follow and connect with him on X, learn about his books at plainfiction.com, or email him directly at christopher@thedebrief.org.

In a groundbreaking advancement for cardiovascular science, researchers at the Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC) in Spain, in collaboration with the Karolinska Institute in Sweden, have devised a cutting-edge technique to analyze the proteome of individual cardiomyocytes. These cells, essential for heart contraction, have long eluded comprehensive single-cell proteomic scrutiny due to technological limitations. This novel approach now allows for a detailed protein-level characterization of single heart muscle cells, opening unprecedented avenues for understanding heart biology and regeneration.

The heart has traditionally been viewed as an organ comprised of relatively homogeneous cardiomyocytes. However, recent findings highlight remarkable heterogeneity even within this single cell type. Variability in protein expression among cardiomyocytes may underpin differences in their functional capacity and regenerative potential. This study, published in Genome Biology, leverages an innovative integration of optimized cell isolation methods, advanced mass spectrometry, and sophisticated bioinformatic algorithms to dissect this proteomic diversity with extraordinary precision.

Central to their investigation was Myc, a transcription factor already noted for its role in regenerative strategies for heart repair. Despite its promise, until now the specific mechanisms by which Myc modulates protein expression in individual cardiomyocytes remained elusive. Applying their novel single-cell proteomics technology, the researchers uncovered that Myc expression differentially alters metabolic enzyme levels across single cardiomyocytes. This heterogeneity results in a subset of cells exhibiting distinct immature states, which in turn possess enhanced regenerative potential—a finding that transforms our comprehension of how cardiac regeneration might be selectively targeted.

The technical feat achieved by these scientists hinges on the fusion of multiple cutting-edge methodologies. First, the meticulous isolation of adult mouse cardiomyocytes ensures viable, intact cells reflecting true physiological states. These cells then undergo mass spectrometry procedures tailored for minute sample volumes, capable of identifying thousands of proteins with high sensitivity and quantitative accuracy at the single-cell level. The ensuing data are processed with bespoke computational pipelines designed to handle the intrinsic variability and noise characteristic of single-cell omics measurements.

By revealing the proteomic fingerprints that distinguish a pro-regenerative subpopulation of cardiomyocytes, this research elucidates a previously uncharted layer of cardiac cellular complexity. Understanding how Myc drives metabolic remodeling at the protein level provides a molecular explanation for its regenerative effects and establishes a foundation for engineering therapeutic approaches that harness or mimic these cellular states.

Regeneration in the adult mammalian heart remains a formidable challenge, owing largely to the low intrinsic capacity of cardiomyocytes to proliferate or replace damaged tissue after injury such as myocardial infarction. Previous models relying largely on bulk tissue analyses have masked the nuanced cellular dynamics at play. This single-cell approach offers resolution sufficient to detect rare but critical cell subsets that might hold the key to effective myocardial repair.

Moreover, this study underscores the transformative impact of integrating proteomics with single-cell biology, moving beyond transcriptomic analyses that often fail to predict functional protein abundance accurately. Proteins, as the primary effectors of cellular function, are the crucial link between gene regulation and phenotype. Hence, this proteomic lens provides a direct readout of the biochemical state of cardiomyocytes under regenerative cues.

The implications of this work extend beyond cardiac biology. It exemplifies the broader potential of single-cell proteomics to deepen our grasp of cellular heterogeneity in health and disease, from cancer biology to neurodegeneration. The refinement and dissemination of such methodologies will empower researchers across biomedical fields to uncover subtle but impactful cellular states previously hidden in ensemble measurements.

Miguel Torres and Jesús Vázquez, who co-led the CNIC teams responsible for this study, emphasize the critical novel insights gained. According to them, dissecting Myc’s action at the single-cell level illuminates pathways and protein networks that govern cellular immaturity and regeneration, which are masked in population-level studies. This knowledge fundamentally shifts how regenerative medicine strategies might be designed, focusing on targeted modulation of key proteins identified within pro-regenerative cardiomyocyte subgroups.

Consuelo Marín-Vicente, the study’s first author, highlights the heterogeneous response to Myc induction in adult cardiomyocytes. Instead of a uniform effect, Myc induces diverse proteomic profiles, driving some cells toward a state primed for regeneration. This discovery points to the existence of intrinsic regulatory mechanisms that govern cardiomyocyte plasticity, with possible manipulation routes to expand these favorable subpopulations therapeutically.

This advancement also signifies a leap toward personalized regenerative therapies. By characterizing the protein signatures specific to regenerative-competent cardiomyocytes, future interventions could selectively enhance these signatures in patient hearts, enabling more effective recovery post-injury. It also offers biomarkers to monitor therapeutic efficacy or to stratify patients likely to benefit from Myc-based or related regenerative treatments.

The CNIC, recognized as a Severo Ochoa Center of Excellence and funded by a unique public-private partnership, remains at the forefront of cardiovascular research. Under the leadership of Dr. Valentín Fuster, CNIC’s mission to translate scientific discoveries into clinical innovations is exemplified by this study’s promise. Collaboration with leading international centers like the Karolinska Institute further underscores the global effort to unravel heart regeneration’s complexity.

In sum, by pioneering a technique for single-cell proteomic analysis of adult cardiomyocytes, this research opens transformative possibilities for cardiovascular medicine. It elucidates how transcription factors like Myc can orchestrate heterogeneous proteomic landscapes within single cells, generating subpopulations equipped with regenerative capabilities. These insights herald a new era in designing precision therapies that could one day restore heart function after injury, dramatically improving outcomes for millions suffering from cardiovascular diseases worldwide.

---

Subject of Research: Cells

Article Title: Pro-regenerative fingerprints identified in a sub-population of adult mouse cardiomyocytes by integrative single-cell proteomics

News Publication Date: 22-May-2026

Web References:
10.1186/s13059-026-04110-1

Image Credits: CNIC

Keywords

Cardiomyocytes, Single-cell proteomics, Myc transcription factor, Heart regeneration, Mass spectrometry, Cellular heterogeneity, Cardiovascular disease, Protein expression, Regenerative medicine, Proteome, Metabolic enzymes, Cardiovascular research

In a groundbreaking study published in Cell Death Discovery, researchers have unveiled a novel mechanism by which Helicobacter pylori, the notorious gastric pathogen, drives the formation and persistence of gastric cancer through a process termed the “hit-and-run” legacy. This research elucidates how transient infection by H. pylori delivers a lasting epigenetic imprint on gastric epithelial cells, effectively locking these cells into a survival mode that fosters oncogenesis. The implications of these findings are profound, offering fresh insights into the molecular interplay between infection-induced epigenetic modification and cancer development, which could pave the way for revolutionary diagnostic and therapeutic strategies.

Helicobacter pylori has long been established as a principal carcinogen associated with gastric cancer, a malignancy ranking among the world’s deadliest. Traditionally, the carcinogenic potential of H. pylori has been attributed to chronic inflammation and the persistent presence of bacterial virulence factors that continuously disrupt gastric mucosa homeostasis. However, the current study challenges this paradigm by demonstrating that even transient exposure to H. pylori can induce stable, heritable epigenetic alterations that effectively “lock” the cellular genome into an aberrant state, independent of ongoing infection. This “hit-and-run” mechanism underscores the importance of early, possibly even brief, pathogen-host interactions in cancer genesis.

At the heart of this discovery is the concept of epigenetic locking—a process through which transient signals induce durable modifications in DNA methylation and histone patterns, which subsequently enforce gene expression profiles conducive to cell survival and proliferation. The group led by Sun, Hu, and Traub employed state-of-the-art genome-wide methylation profiling alongside chromatin immunoprecipitation sequencing (ChIP-seq) to map the intricate epigenetic landscapes shaped by H. pylori infection. Their findings revealed a marked enrichment of repressive histone marks on tumor suppressor gene loci and a reduction in methylation at key oncogenic enhancers, a dual mechanism that effectively enables gastric epithelial cells to bypass apoptosis and adopt a resilient phenotype.

Intriguingly, the authors identified a “survival switch” embedded within the epigenetic circuitry, which perpetuates cell viability in the hostile gastric environment despite the absence of the pathogen. This survival pathway hinges on the modulation of several critical transcription factors and downstream effectors that drive resistance to oxidative stress and immune checkpoint evasion. The persistence of this switch presents a formidable barrier to therapeutic intervention, explaining the often-observed resistance and relapse seen in conventional anti-H. pylori and chemotherapeutic regimes.

The study further explores the timing and sequence of epigenetic alterations following H. pylori infection. Temporal analysis demonstrated that initial infection triggers a wave of epigenetic remodeling within days, with key changes becoming fixed in the genome over weeks, thus confirming the durability of the modifications. This rapid “imprinting” emphasizes the need for early detection and intervention post infection to prevent the establishment of irreversible oncogenic programs.

Mechanistically, the team delved into the role of bacterial virulence factors such as CagA and VacA in orchestrating these epigenetic changes. They postulate that CagA, upon translocation into host cells, interacts with host chromatin modifiers and signaling pathways like NF-kB and STAT3, initiating cascades that culminate in altered chromatin architecture. VacA further modulates cellular metabolism and stress responses, cumulatively fixing the epigenetic landscape conducive to cancer progression.

The implications of the “hit-and-run” model extend beyond H. pylori-induced gastric cancer, provoking reconsideration of how transient infections may contribute to other epigenetically driven malignancies. This paradigm shift advocates for a broader investigation into the long-term impact of infectious insults at the epigenome level, potentially revolutionizing the standard view of tumorigenesis associated with microbial pathogens.

Therapeutically, the study stimulates the development of epigenetic-targeted approaches aimed at “unlocking” these stable aberrations. By reversing methylation patterns or disrupting the survival networks sustained by epigenetic modifications, it may become possible to sensitize tumor cells to existing chemotherapies or to immune-mediated clearance. The prospect of integrating epigenetic therapy into the clinical management of H. pylori-associated gastric cancer represents a promising frontier.

Moreover, diagnostic innovation could also benefit from these findings. Epigenetic biomarkers identified through this research may serve as early indicators of cancer risk in patients with a history of H. pylori infection, enabling stratification and personalized surveillance. The early detection of epigenetic locking signatures in gastric mucosa could dramatically improve prognosis by facilitating timely therapeutic intervention.

The study’s comprehensive exploration of epigenetic changes was bolstered by the use of gastric organoids and in vivo models, which authentically recapitulated the cellular and tissue contexts of H. pylori infection. This multi-faceted experimental design lent robust physiological relevance to the findings and highlighted the dynamic interplay between pathogen factors and host epigenomic machinery.

Collectively, this research not only deciphers the cryptic molecular legacy left by H. pylori but also refines our understanding of infection-associated carcinogenesis. The “hit-and-run” legacy paradigm sheds light on the complex, often covert, mechanisms through which transient pathogen interactions exert long-lasting oncogenic effects, shifting both scientific insight and clinical approach.

In summary, the work by Sun, Hu, Traub, and colleagues heralds a new era in gastric cancer biology, emphasizing the critical role of infection-driven epigenetic programming. As further investigations build upon this foundation, multidisciplinary efforts encompassing microbiology, epigenetics, and cancer therapeutics will be essential to translate these insights into tangible clinical applications.

The future of combatting H. pylori-associated gastric cancer lies not only in eradicating the bacteria but also in decoding and reversing the epigenetic codes it inscribes. This endeavor carries the promise of transforming patient outcomes, potentially mitigating one of the world’s most lethal cancers with strategies born from the understanding of the pathogen’s epigenetic “hit-and-run” legacy.

---

Subject of Research: Epigenetic mechanisms underlying the persistence and oncogenic transformation in Helicobacter pylori-associated gastric cancer.

Article Title: The “Hit-and-Run” legacy: epigenetic locking and the survival switch in H. pylori-associated gastric cancer.

Article References:
Sun, J., Hu, P., Traub, B. et al. The “Hit-and-Run” legacy: epigenetic locking and the survival switch in H. pylori-associated gastric cancer. Cell Death Discov. (2026). https://doi.org/10.1038/s41420-026-03210-y

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41420-026-03210-y